• Mashup Score: 4

    Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued

    Tweet Tweets with this article
    • Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb88Zl & https://t.co/6vxGpOv5PJ #PrecisionMedicine #CUPsm @TempusLabs

  • Mashup Score: 0

    OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,

    Tweet Tweets with this article
    • The genomic landscape of small cell lung cancer in never smoking patients [Sep 12, 2022] Oh et al. #ESMO22 Oral Discussion (1529MO) https://t.co/Mo8i55iK4Y #PrecisionMedicine #lcsm @UCLA @dgsomucla @TempusLabs

  • Mashup Score: 1

    OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,

    Tweet Tweets with this article
    • BRAF mutations and fusions in a real-world cohort of non-small cell lung cancer patients [Sep 12, 2022] Niu et al. #ESMO22 Abstract 1107P https://t.co/l8uUlYKK6P #PrecisionMedicine #lcsm @Bannermdandersn @TempusLabs

  • Mashup Score: 0

    Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued

    Tweet Tweets with this article
    • Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb8GOT & https://t.co/6vxGpOvDFh #PrecisionMedicine #CUPsm @TempusLabs

  • Mashup Score: 0

    OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,

    Tweet Tweets with this article
    • The genomic landscape of small cell lung cancer in never smoking patients [Sep 12, 2022] Oh et al. #ESMO22 Oral Discussion (1529MO) https://t.co/Mo8i55jhUw #PrecisionMedicine #lcsm @UCLA @dgsomucla @TempusLabs

  • Mashup Score: 0

    OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,

    Tweet Tweets with this article
    • BRAF mutations and fusions in a real-world cohort of non-small cell lung cancer patients [Sep 12, 2022] Niu et al. #ESMO22 Abstract 1107P https://t.co/l8uUlYLhWn #PrecisionMedicine #lcsm @Bannermdandersn @TempusLabs

  • Mashup Score: 0

    Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued

    Tweet Tweets with this article
    • Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb88Zl & https://t.co/6vxGpOv5PJ #PrecisionMedicine #CUPsm @TempusLabs